Leerink Partnrs Expects Reduced Earnings for Schrödinger

Schrödinger, Inc. (NASDAQ:SDGRFree Report) – Equities research analysts at Leerink Partnrs decreased their FY2024 EPS estimates for shares of Schrödinger in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($2.11) per share for the year, down from their previous estimate of ($1.99). The consensus estimate for Schrödinger’s current full-year earnings is ($2.29) per share. Leerink Partnrs also issued estimates for Schrödinger’s Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($2.16) EPS and FY2026 earnings at ($2.73) EPS.

Schrödinger (NASDAQ:SDGRGet Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The firm had revenue of $35.30 million during the quarter, compared to analyst estimates of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. Schrödinger’s quarterly revenue was down 17.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.86) earnings per share.

A number of other research analysts have also recently issued reports on the company. BMO Capital Markets lifted their price target on Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. KeyCorp upped their target price on shares of Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.10.

View Our Latest Report on SDGR

Schrödinger Price Performance

NASDAQ SDGR opened at $24.67 on Friday. The stock’s 50 day simple moving average is $20.71 and its 200 day simple moving average is $20.08. Schrödinger has a one year low of $16.67 and a one year high of $33.63. The firm has a market cap of $1.80 billion, a PE ratio of -10.54 and a beta of 1.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP grew its holdings in shares of Schrödinger by 17.7% in the 3rd quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company’s stock valued at $68,366,000 after buying an additional 555,503 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Schrödinger by 1.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,191,054 shares of the company’s stock worth $40,644,000 after buying an additional 29,920 shares during the period. State Street Corp boosted its position in Schrödinger by 1.8% during the 3rd quarter. State Street Corp now owns 2,155,620 shares of the company’s stock worth $39,987,000 after acquiring an additional 38,972 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Schrödinger by 58.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,945,182 shares of the company’s stock valued at $36,083,000 after purchasing an additional 717,059 shares in the last quarter. Finally, Stephens Investment Management Group LLC increased its stake in Schrödinger by 39.6% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,539,870 shares of the company’s stock valued at $28,565,000 after buying an additional 436,789 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Schrödinger Company Profile

(Get Free Report)

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.

Featured Articles

Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.